Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-03
2009-10-27
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S649000, C514S676000
Reexamination Certificate
active
07608616
ABSTRACT:
Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination.
REFERENCES:
patent: 6344487 (2002-02-01), Kavey
Thase ME. “Treatment Issues Related to Sleep and Depression”. J Clin Psychiatry, 2000; 61[Suppl 11]:46-50.
Kales A. “Quazepam: Hypnotic Efficacy and Side Effects”. Pharmacotherapy, 1990; 10(1):1-12.
Reid et al. “Insomnia in HIV Infection: A Systematic Review of Prevalence, Correlates, and Management”. Psychosomatic Medicine, 2005; 67:260-269.
Gallego et al. “Abnormalities in Sleep Architecture in Patients Receiving Efavirenz”. Retrovir Oppor Infect 10th 2002 Boston Mass. Feb. 10-14, 2003; 10: Abstract No. 716.
Nakao et al. “Major Depression and Somatic Symptoms in a Mind/Body Medicine Clinic”. Psychopathology; Sep./Oct. 2001; 34(5):230-235.
Akhondzadeh et al. “Double-Blind Comparison of Fluoxetine and Nortriptyline in the Treatment of Moderate to Severe Major Depression”. Journal of Clinical Pharmacy and Therapeutics. 2003; 28:379-384.
Bupropion Information from Wikipedia Revision as of 3:32, Jun. 3, 2007; http://en.wikipedia.org/wiki/Bupropion.
Turpeinen, M. et al., “Cytochrome P450 (CYP) inhibition screening: Comparison of three tests,” Eur. J. Pharmaceutical Sciences 29:130-138 (2006).
Walsky, W.L. et al., “Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6,” J. Clin. Pharmacol. 46:1426-1438 (2006).
Wellbutrin XL Medication Guide, Aug. 2007 manufactured by Biovail Corporation for GlaxoSmithKline.
Clifford, D.B. et al., “Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals,” Ann. Intern. Med. 143:714-721 (2006).
Gallego, L. et al., “Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz,” CID 38:430-432 (2004).
“Most Effective Initial Therapy For HIV-1 Infection Identified,” Science Daily, http://www.sciencedaily.com/releases/2008/05/08051417814.htm, (2008).
Riddler, S.A. et al., “Class-Sparing Regiments for Initial Treatment of HIV-1 Infection,” N. Engl. J. Med. 358(20):2095-2106 (2008).
Marschel Ardin
Questcor Pharmaceuticals, Inc.
Royds Leslie A
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods for reducing the risk of an adverse drug interaction... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reducing the risk of an adverse drug interaction..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing the risk of an adverse drug interaction... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064070